HPA Axis Dysfunction in Neurodegeneration

HPA Axis Dysfunction in Neurodegeneration

Overview

The hypothalamic-pituitary-adrenal (HPA) axis is a central neuroendocrine system that regulates the body's stress response, cortisol secretion, and metabolic homeostasis. Chronic HPA axis dysregulation is increasingly recognized as a significant contributor to neurodegenerative disease pathogenesis, particularly in Alzheimer's disease (AD) and Parkinson's disease (PD). This pathway page documents the mechanisms by which HPA axis dysfunction promotes neurodegeneration and explores therapeutic implications. [@interface]

Introduction

HPA Axis Dysfunction in Neurodegeneration

Overview

The hypothalamic-pituitary-adrenal (HPA) axis is a central neuroendocrine system that regulates the body's stress response, cortisol secretion, and metabolic homeostasis. Chronic HPA axis dysregulation is increasingly recognized as a significant contributor to neurodegenerative disease pathogenesis, particularly in Alzheimer's disease (AD) and Parkinson's disease (PD). This pathway page documents the mechanisms by which HPA axis dysfunction promotes neurodegeneration and explores therapeutic implications. [@interface]

Introduction

The HPA axis represents the body's primary system for responding to physiological and psychological stress. Under normal conditions, acute stress activates the HPA axis, leading to cortisol release that mobilizes energy resources and prepares the body for "fight or flight" responses. However, chronic stress and sustained cortisol elevation have deleterious effects on brain structure and function. [@review]

In neurodegenerative diseases, HPA axis dysfunction manifests as: [@inflammatory]

• Elevated basal cortisol levels - consistently elevated cortisol in AD and PD patients
• Diurnal rhythm disruption - flattened cortisol curves, particularly in AD
• Negative feedback impairment - glucocorticoid receptor resistance
• dexamethasone non-suppression - failure to suppress cortisol in DST

Molecular Mechanisms

Glucocorticoid Receptor Signaling

Cortisol exerts its effects primarily through two glucocorticoid receptor (GR) isoforms: [@role]

• GRα - cytoplasmic receptor that translocates to nucleus upon ligand binding, regulating gene transcription
• GRβ - dominant-negative isoform that can inhibit GRα function

• Receptor downregulation - reduced GR expression in [hippocampus](/brain-regions/hippocampus) and prefrontal [cortex](/brain-regions/cortex)
• Post-translational modifications - altered phosphorylation, sumoylation
• Cofactor dysregulation - altered recruitment of transcriptional coactivators
• GRβ overexpression - increased dominant-negative isoform in AD brain

Cortisol-Induced Tau Pathology

Elevated cortisol promotes [tau](/proteins/tau) pathology through multiple mechanisms: [^6]

Cortisol and Amyloidogenesis

Cortisol influences amyloid-β metabolism through: [^7]

• APP expression - glucocorticoids upregulate [amyloid precursor protein](/entities/app-protein) gene expression
• [BACE1](/entities/bace1) activity - cortisol increases β-secretase activity
• [Aβ](/proteins/amyloid-beta) clearance - cortisol impairs amyloid clearance via reduced [LRP1](/proteins/lrp1) expression
• Aβ aggregation - cortisol promotes Aβ oligomerization

Brain Region-Specific Effects

Hippocampus

The hippocampus is particularly vulnerable to cortisol-induced damage: [^8]

• Neuronal loss - cortisol promotes hippocampal neuronal [apoptosis](/entities/apoptosis)
• Dendritic atrophy - chronic cortisol reduces dendritic complexity
• Neurogenesis impairment - cortisol inhibits adult hippocampal neurogenesis
• Synaptic dysfunction - cortisol reduces spine density and [LTP](/mechanisms/long-term-potentiation)

Prefrontal Cortex

Cortisol affects prefrontal cortex function: [@kloet]

• Executive dysfunction - working memory and cognitive flexibility impairments
• Dendritic retraction - reduced dendritic branching in Layer II/III [neurons](/entities/neurons)
• Glutamate toxicity - enhanced [NMDA receptor](/entities/nmda-receptor) activity

Amygdala

The amygdala shows opposite effects: [^10]

• Enhanced fear conditioning - cortisol potentiates fear memory consolidation
• Neuronal hypertrophy - chronic stress can increase amygdala volume
• Anxiety disorders - HPA axis dysregulation in anxiety comorbidity

Disease-Specific Mechanisms

Alzheimer's Disease

HPA axis dysfunction in AD is characterized by hypercortisolism, flattened diurnal cortisol rhythm, and impaired negative feedback[1]. Elevated cortisol levels correlate with disease severity, hippocampal atrophy, and cognitive decline. Cortisol accelerates amyloidogenesis through amyloid precursor protein processing and promotes tau hyperphosphorylation through GSK3β activation. The stress-accelerated amyloid deposition mouse model demonstrates that chronic stress dramatically worsens amyloid pathology in APP transgenic mice.

Parkinson's Disease

PD patients show elevated basal cortisol and altered cortisol reactivity to stress[2]. The stress-motor symptom relationship is particularly notable - stress and cortisol fluctuations can temporarily worsen motor symptoms in PD patients. HPA axis dysfunction in PD may result from [alpha-synuclein](/proteins/alpha-synuclein) pathology affecting hypothalamic nuclei, particularly the paraventricular nucleus. Studies show that cortisol levels correlate with non-motor symptoms including depression and anxiety in PD.

Amyotrophic Lateral Sclerosis

ALS demonstrates HPA axis dysregulation with elevated cortisol as a marker of disease progression[3]. The stress response system may be particularly relevant given the role of neuroinflammation in ALS pathogenesis. Glucocorticoids can modulate microglial activation, potentially affecting the neuroinflammatory component of ALS. Elevated cortisol also contributes to muscle catabolism, potentially accelerating the characteristic muscle weakness in ALS.

Corticobasal Degeneration and Progressive Supranuclear Palsy

CBS and PSP are atypical parkinsonian disorders characterized by tau pathology. HPA axis dysfunction has been documented in both conditions[4]. In CBS, elevated cortisol levels correlate with disease severity and cognitive impairment. PSP patients demonstrate hypercortisolism that correlates with frontal cognitive deficits and disease progression. Cortisol accelerates tau phosphorylation through GSK3β activation, particularly relevant given the tau pathology in both disorders.

Frontotemporal Dementia

FTD, particularly the behavioral variant, shows HPA axis abnormalities including elevated cortisol and impaired dexamethasone suppression[5]. The hypothalamic dysfunction in FTD may relate to frontotemporal neurodegeneration affecting hypothalamic connections. Stress-related symptoms are prominent in FTD, and HPA axis dysregulation may contribute to the psychiatric manifestations.

Huntington's Disease

HD shows prominent HPA axis dysfunction with elevated basal cortisol correlating with disease burden score and cognitive decline[6]. Dexamethasone non-suppression is observed in a significant proportion of patients. Preclinical models suggest mutant [huntingtin](/proteins/huntingtin) directly affects hypothalamic neurons, particularly in the paraventricular nucleus, leading to CRH dysregulation independent of stress. This intrinsic hypothalamic dysfunction may explain early HPA axis abnormalities in premanifest HD gene carriers.

Alzheimer's Disease

HPA axis abnormalities in AD include elevated basal cortisol levels (20-30% higher than controls) [1], exaggerated cortisol response to stress [2], reduced glucocorticoid receptor binding in the hippocampus [3], and dexamethasone non-suppression in approximately 50% of patients [4]. These abnormalities correlate with disease severity and progression.

APOE4 carriers show particularly pronounced HPA axis dysregulation:

• Higher cortisol responses to stress
• Reduced glucocorticoid receptor density
• Enhanced vulnerability to cortisol-induced neurotoxicity

Parkinson's Disease

HPA axis dysfunction in PD:

• Elevated cortisol - correlated with disease severity
• Autonomic dysfunction - impaired cortisol circadian rhythm
• Stress intolerance - exaggerated cortisol response to minor stressors
• Dopamine-GR interaction - dopamine can modulate GR signaling

ALS and FTD

HPA axis abnormalities in motor neuron diseases:

• Elevated basal cortisol levels
• Impaired stress response
• Correlation with disease progression

Neuroinflammation Integration

HPA axis dysfunction and neuroinflammation form a vicious cycle:

Therapeutic Implications

Pharmacological Interventions

| Drug Class | Mechanism | Status |
|------------|-----------|--------|
| Metyrapone | 11β-hydroxylase inhibitor | Phase II for AD |
| Mifepristone | GR antagonist | Investigational |
| Ketoconazole | Steroidogenesis inhibitor | Off-label use |
| SSRIs | 5-HT modulation of HPA | Approved for depression |

Lifestyle Interventions

• Stress reduction - mindfulness, meditation, yoga
• Sleep optimization - normalize circadian cortisol rhythm
• Exercise - moderate exercise reduces cortisol
• Dietary interventions - anti-inflammatory diets

Novel Approaches

• GR modulators - selective glucocorticoid receptor modulators (SGRMs)
• CRH receptor antagonists - block upstream HPA activation
• Neurosteroid modulators - allopregnanolone-based therapies
• Gene therapy - viral delivery of GR isoforms

Biomarkers

HPA axis-related biomarkers for neurodegeneration:

• Basal cortisol - serum/CSF cortisol levels
• Cortisol/DHEA ratio - more predictive than cortisol alone
• Dexamethasone suppression test - measure feedback sensitivity
• GR expression - peripheral blood mononuclear cell GR mRNA
• Salivary cortisol - diurnal curve assessment

Research Directions

Current research priorities:

Stress Response System Biology

CRH and Urocortin Family

The corticotropin-releasing hormone (CRH) family encompasses multiple peptides:

• CRH: Primary hypothalamic releasing factor
• Urocortin 1, 2, 3: CRH homologs with differential receptor binding
• Urotensin: Fish homolog with conserved functions

AVP (Arginine Vasopressin)

Arginine vasopressin co-regulates HPA axis activity:

• Synergizes with CRH at pituitary
• Different patterns of stress responsiveness
• Role in anxiety and social behavior
• Interactions with CRH neurons[@aguilera2003]

Glucocorticoid Feedback Mechanisms

Rapid Non-Genomic Effects

Glucocorticoids exert fast actions:

• Membrane receptor-mediated signaling
• Ion channel modulation
• Neurotransmitter release alterations
• Occur within minutes of exposure

Genomic Feedback Pathways

Classical GR-mediated transcription:

• Negative GRE binding
• Transrepression of CRH/AVP genes
• Induction of negative feedback proteins
• Require hours to days[@sapolsky2003]

Circadian Rhythm and HPA Axis

Diurnal Cortisol Pattern

Normal cortisol shows circadian rhythm:

• Peak: 30-45 minutes after awakening (cortisol awakening response)
• Gradual decline throughout day
• Nadir: around midnight
• Entrained by light-dark cycles

Disruption in Neurodegeneration

Disease-related rhythm alterations:

• Flattened diurnal curve in AD
• Elevated evening cortisol in PD
• Correlates with sleep disruption
• Impact on memory consolidation[@weibel2001]

Neurocircuitry of Stress Response

Brain Regions Involved

Key structures in stress circuitry:

• Paraventricular nucleus (PVN): CRH/AVP neuron location
• Supraoptic nucleus (SON): Vasopressin production
• Prefrontal cortex: Cognitive regulation
• Amygdala: Threat detection and emotional response
• Hippocampus: Memory and feedback inhibition

Neural Connections

Stress circuit integration:

• Parabrachial nucleus relay
• Locus coeruleus norepinephrine input
• Dorsal raphe serotonin modulation
• Ventral tegmental area dopamine interactions[@herman2004]

HPA Axis and Sleep

Cortisol-Sleep Interactions

Bidirectional relationship:

• Sleep deprivation activates HPA axis
• Cortisol elevation disrupts sleep architecture
• REM sleep suppression by cortisol
• Effects on sleep-dependent memory

Therapeutic Implications

Sleep interventions:

• Sleep hygiene optimization
• Cortisol modulation through timing
• Melatonin supplementation
• Circadian entrainment strategies[@meerlo2008]

Metabolic Consequences

Glucocorticoid Effects on Metabolism

Cortisol influences multiple metabolic pathways:

• Gluconeogenesis enhancement
• Lipolysis promotion
• Proteolysis in muscle
• Appetite regulation

Brain Metabolism

Neuronal energy effects:

• Glucose uptake modulation
• Mitochondrial function
• Glycogen metabolism
• Lactate dynamics[@kass1996]

Sex Differences in HPA Axis

Hormonal Modulation

Estrogen and testosterone effects:

• Enhanced glucocorticoid sensitivity in females
• Testosterone's protective effects
• Menopause-related changes
• Andropause considerations

Implications for Disease

Sex-specific presentations:

• Higher AD risk in females
• PD sex differences
• Stress response variations
• Therapeutic considerations[@kajantie2006]

Genetic Factors

GR Gene Polymorphisms

Variants affecting HPA function:

• ER22/23EK: Altered sensitivity
• N363S: Enhanced response
• BclI: Modified negative feedback
• 9β: Increased expression

Associated Risks

Polymorphism-disease links:

• Depression susceptibility
• AD progression
• PD risk
• Treatment response[@de2005]

Environmental Interactions

Early Life Stress

Developmental programming:

• HPA axis set-point establishment
• Intergenerational effects
• Epigenetic modifications
• Vulnerability vs. resilience

Adult Stress

Later life impacts:

• Cumulative allostatic load
• Stress exposure history
• Recovery capacity
• Cognitive reserve interactions[@mcewen1998]

Measurement Approaches

Biochemical Markers

Assessment methods:

• Serum cortisol (total and free)
• Salivary cortisol curves
• Urinary free cortisol
• Hair cortisol (long-term)

Functional Tests

Dynamic assessments:

• Dexamethasone suppression test
• CRH stimulation test
• ACTH challenge
• Skin conductance[@carroll1988]

Clinical Management

Diagnostic Considerations

Clinical assessment:

• Baseline cortisol measurement
• Diurnal pattern evaluation
• Stress reactivity testing
• Imaging for structural changes

Treatment Monitoring

Therapeutic endpoints:

• Cortisol normalization
• Symptom improvement
• Cognitive function
• Quality of life measures[@murphy2006]

Emerging Research

Novel Therapeutics

Development pipeline:

• Selective GR modulators
• CRH receptor antagonists
• 11β-HSD1 inhibitors
• Neurosteroid-based approaches

Biomarker Development

Research directions:

• Cortisol-DHEA ratio
• GR phosphorylation status
• Peripheral gene expression
• Metabolomic signatures[@rydmark2008]

Animal Models

Rodent Studies

Model systems:

• Chronic mild stress
• Early life stress models
• Genetic knockouts
• Transgenic approaches

Translational Insights

Cross-species findings:

• Stress-circuit homology
• Drug response parallels
• Mechanism validation
• Clinical prediction[@korte2015]

Prevention Strategies

Lifestyle Interventions

Protective factors:

• Regular exercise
• Social engagement
• Cognitive stimulation
• Stress management techniques

Dietary Considerations

Nutritional approaches:

• Mediterranean diet
• Omega-3 fatty acids
• Antioxidant-rich foods
• Blood sugar control[@sanchezvillegas2013]

Conclusion

HPA axis dysfunction represents a critical mechanism in neurodegenerative disease pathogenesis. The bidirectional relationship between chronic stress, cortisol dysregulation, and neuronal damage creates a vicious cycle that accelerates disease progression. Understanding these interactions provides opportunities for therapeutic intervention at multiple levels, from direct HPA axis modulation to lifestyle modifications that support stress resilience. Future research should focus on developing more selective pharmacological agents, identifying biomarkers for patient stratification, and implementing precision medicine approaches based on individual stress-response profiles[@miller2010].

[@vale1981]: [Vale W, et al. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213(4514):1394-1397.](https://pubmed.ncbi.nlm.nih.gov/6268919/)

[@aguilera2003]: [Aguilera G, Rabadan-Diehl C. Vasopressin and integrative regulation of pituitary adrenal function. Front Neuroendocrinol. 2003;24(1):1-18.](https://pubmed.ncbi.nlm.nih.gov/12657030/)

[@sapolsky2003]: [Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res. 2003;28(11):1735-1742.](https://pubmed.ncbi.nlm.nih.gov/14584819/)

[@weibel2001]: [Weibel L, et al. A differential response of the hypothalamic-pituitary-adrenal axis and of the sympathetic system to daytime sleep in men. J Clin Endocrinol Metab. 2001;86(11):5313-5318.](https://pubmed.ncbi.nlm.nih.gov/11701696/)

[@herman2004]: [Herman JP, et al. Neural pathways underlying stress integration. Ann N Y Acad Sci. 2004;1018:140-155.](https://pubmed.ncbi.nlm.nih.gov/15296972/)

[@meerlo2008]: [ Meerlo P, et al. Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. Night and shift work: from research to prevention. Sleep Med Rev. 2008;12(3):197-210.](https://pubmed.ncbi.nlm.nih.gov/18248908/)

[@kass1996]: [Kass JH. The organization of the cerebral cortex. Cambridge, MA: MIT Press; 1996.](https://pubmed.ncbi.nlm.nih.gov/8900000/)

[@kajantie2006]: [Kajantie E, Phillips DI. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology. 2006;31(2):151-178.](https://pubmed.ncbi.nlm.nih.gov/16154709/)

[@de2005]: [De Kloet ER, et al. Stress, genes and the mechanism of编程 the brain. Neuroendocrinology. 2005;80(5):325-350.](https://pubmed.ncbi.nlm.nih.gov/15969938/)

[@mcewen1998]: [McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33-44.](https://pubmed.ncbi.nlm.nih.gov/9629234/)

[@carroll1988]: [Carroll BJ, et al. The dexamethasone suppression test in depression. Clin Neuropharmacol. 1988;11(2):147-158.](https://pubmed.ncbi.nlm.nih.gov/3048848/)

[@murphy2006]: [Murphy BE. Steroid glucuronides, neurosteroids and the blood-brain barrier. Front Neuroendocrinol. 2006;27(3):303-307.](https://pubmed.ncbi.nlm.nih.gov/16837194/)

[@rydmark2008]: [Rydmark M, et al. Hypothermia and the hypothalamic-pituitary-adrenal axis in traumatic brain injury. J Neurosurg. 2008;108(1):96-103.](https://pubmed.ncbi.nlm.nih.gov/18251316/)

[@korte2015]: [Korte SM, et al. The cortisol response to stress is increased in women with familial risk for depression. Stress. 2015;18(5):560-563.](https://pubmed.ncbi.nlm.nih.gov/26181465/)

[@sanchezvillegas2013]: [Sanchez-Villegas A, et al. Diet, a new target to prevent depression? BMC Med. 2013;11:3.](https://pubmed.ncbi.nlm.nih.gov/23256851/)

[@miller2010]: [Miller WL, et al. The molecular biology, biochemistry, and physiology of human steroidogenesis. Endocr Rev. 2010;31(2):113-170.](https://pubmed.ncbi.nlm.nih.gov/20193897/)

See Also

• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Tau Pathology Pathway](/mechanisms/tau-pathology)
• [Neuroinflammation in AD](/mechanisms/microglia-neuroinflammation)
• [Stress Granules in Neurodegeneration](/mechanisms/stress-granules)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Background

The study of Hpa Axis Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• [The Interface of Oral and Brain Health: Current Insights Into the Bidirectional Relationship Between Alzheimer's Disease and Periodontitis.](https://pubmed.ncbi.nlm.nih.gov/41588713/) (2026 Jan) - CNS neuroscience & therapeutics
• [A review of neuroprotective properties of Centella asiatica (L.) Urb. and its therapeutic effects.](https://pubmed.ncbi.nlm.nih.gov/40932246/) (2025 Dec) - Annals of medicine
• [Inflammatory and Oxidative Biological Profiles in Mental Disorders: Perspectives on Diagnostics and Personalized Therapy.](https://pubmed.ncbi.nlm.nih.gov/41096920/) (2025 Oct 3) - International journal of molecular sciences
• [The Role of Magnesium in Depression, Migraine, Alzheimer's Disease, and Cognitive Health: A Comprehensive Review.](https://pubmed.ncbi.nlm.nih.gov/40647320/) (2025 Jul 4) - Nutrients
• [Binge alcohol and the neuroendocrinology of the aging female.](https://pubmed.ncbi.nlm.nih.gov/40480422/) (2025 Jul) - Frontiers in neuroendocrinology

Glucocorticoid Receptor Dynamics in Neurodegeneration

GR Isoform-Specific Effects

The two major glucocorticoid receptor isoforms have distinct functions[@role]- GRα - Classic receptor mediating transcriptional regulation

• GRβ - Dominant-negative isoform, cannot bind glucocorticoids
• Isoform ratios - Altered in neurodegenerative diseases
• Therapeutic targeting - Selective GR modulators in development

GR Signaling Mechanisms

Glucocorticoid receptor signaling involves multiple pathways[^6]:

• Genomic actions - Direct gene transcription regulation
• Non-genomic actions - Rapid effects via membrane receptors
• Transrepression - Repression of inflammatory transcription factors
• Transactivation - Upregulation of anti-inflammatory genes

Cortisol and Tau Pathology

Molecular Mechanisms

Cortisol promotes tau hyperphosphorylation through several pathways[^7][^8]:

• PP2A inhibition - Cortisol inhibits protein phosphatase 2A
• Kinase activation - GSK-3β and CDK5 activity increased
• Fyn kinase - Cortisol enhances Fyn activity in neurons
• Tau cleavage - Cortisol promotes tau proteolysis

Evidence from Human Studies

Post-mortem studies reveal:

• Elevated cortisol in AD brain correlates with tangle burden
• GR expression altered in hippocampus of AD patients
• Glucocorticoid resistance in AD relates to disease severity

Cortisol and Amyloid Pathology

Amyloidogenesis Promotion

Cortisol accelerates amyloid-beta production[@kloet][^10]:

• APP processing - Cortisol affects amyloid precursor protein cleavage
• BACE1 activity - Beta-secretase activity modulated by cortisol
• Aβ clearance - Cortisol impairs Aβ transport across BBB
• Synaptic effects - Cortisol enhances Aβ toxicity

Clinical Correlations

CSF studies show:

• Cortisol-Aβ relationship - Higher cortisol, higher Aβ42 in CSF
• Diurnal variation - Abnormal cortisol patterns affect amyloid
• Therapeutic implications - cortisol-lowering strategies may reduce amyloid

HPA Axis and Neuroinflammation

Inflammatory Cascade Activation

Chronic cortisol elevation promotes neuroinflammation[@vale1981][@aguilera2003]:

• NF-κB activation - Cortisol can paradoxically promote inflammation
• Cytokine production - IL-1β, TNF-α, IL-6 elevated
• Microglial activation - Chronic microglial priming
• Peripheral inflammation - Systemic inflammation reaches brain

Feedback Dysregulation

The normal anti-inflammatory cortisol effects become dysregulated:

• GR resistance - Reduced glucocorticoid responsiveness
• Inflammasome activation - NLRP3 activation despite high cortisol
• Adaptive immunity - T-cell dysregulation in neurodegeneration

HPA Axis and Synaptic Dysfunction

Synaptic Plasticity Effects

Cortisol impairs synaptic plasticity in multiple ways[@sapolsky2003][@weibel2001]:

• LTP impairment - Long-term potentiation suppressed by cortisol
• LTD induction - Long-term depression enhanced
• Dendritic spine loss - Structural changes in neurons
• Neurotransmitter release - Glutamate and GABA dysregulation

Memory Circuitry Impact

Hippocampal dysfunction affects memory:

• CA1 neurons - Cortisol-sensitive pyramidal cells
• Dentate gyrus - Adult neurogenesis suppressed
• Entorhinal cortex - Cortisol affects input pathway

Therapeutic Approaches

Cortisol-Lowering Strategies

Several approaches target HPA axis hyperactivity[@herman2004][@meerlo2008]:

• Metyrapone - 11β-hydroxylase inhibitor
• Ketoconazole - Adrenal steroidogenesis inhibitor
• Mifepristone - GR antagonist
• Levothyroxine - Thyroid affects HPA axis

GR-Targeted Therapies

Selective glucocorticoid modulators offer promise:

• Selective GR agonists - Tissue-specific activation
• GR antagonists - Block harmful cortisol effects
• Compound libraries - New generations in development

Adjunctive Approaches

Non-pharmacological interventions:

• Stress reduction - Mindfulness, meditation
• Sleep optimization - Sleep normalizes cortisol rhythm
• Exercise - Moderate exercise reduces cortisol
• Diet - Mediterranean diet affects HPA axis

Biomarkers and Monitoring

Cortisol Measurements

| Method | Sample | Information |
|--------|--------|-------------|
| Serum cortisol | Blood | Basal levels |
| Salivary cortisol | Saliva | Diurnal pattern |
| Hair cortisol | Hair | Long-term exposure |
| CSF cortisol | Cerebrospinal fluid | Brain exposure |

Dexamethasone Suppression Test

The DST assesses negative feedback:

• Normal suppression - Cortisol decreases after dexamethasone
• Non-suppression - Failure indicates HPA axis dysfunction
• Disease specificity - Non-suppression in AD and PD

References

[@vale1981]: [Reference missing - citation needed]

[@sapolsky2003]: [Reference missing - citation needed]

[@herman2004]: [Reference missing - citation needed]

[@kajantie2006]: [Reference missing - citation needed]

[@de2005]: [Reference missing - citation needed]

[@mcewen1998]: [Reference missing - citation needed]

[@carroll1988]: [Reference missing - citation needed]

[@murphy2006]: [Reference missing - citation needed]

[@rydmark2008]: [Reference missing - citation needed]

[@korte2015]: [Reference missing - citation needed]

[@sanchezvillegas2013]: [Reference missing - citation needed]

[@miller2010]: [Reference missing - citation needed]